Can Moderna Repeat COVID-19 Success In Influenza Market?

First Subject Dosed In Flu Vaccine Trial

 
• By Alaric DeArment

The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.  

Influenza A H7N9
Moderna announced that the first subject in its Phase I/II study of its mRNA influenza vaccine was dosed • Source: Shutterstock

With proof of concept under its belt thanks to the success of its COVID-19 vaccine, Moderna, Inc. could have a significant competitive advantage in the influenza vaccine market with mRNA-1010, especially if it can successfully fulfill its aim to combine it with other respiratory virus vaccines, namely a booster against SARS-CoV-2 and a vaccine against respiratory syncytial virus (RSV).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas